

# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

- (51) International Patent Classification <sup>6</sup>:

  C07D 473/34

  A1

  (11) International Publication Number: WO 99/29694

  (43) International Publication Date: 17 June 1999 (17.06.99)
- (21) International Application Number: PCT/US98/26444

12 December 1997 (12.12.97)

- (22) International Filing Date: 11 December 1998 (11.12.98)
- (71) Applicant (for all designated States except US):
  EURO-CELTIQUE, S.A. [LU/LU]; 122, boulevard de la Petrusse, L-2330 Luxembourg (LU).
- (72) Inventors; and

(30) Priority Data:

60/069,371

- (75) Inventors/Applicants (for US only): CAVALLA, David [GB/GB]; 5 Tenison Avenue, Cambridge CB1 2DX (GB). CHASIN, Mark [US/US]; 3 Wayne Court, Manalapan, NJ 07726 (US). HOFER, Peter [CH/CH]; Birmannstrasse 9, CH-4410 Liestal (CH).
- (74) Agents: DAVIDSON, Clifford, M. et al.; Davidson, Davidson & Kappel, LLC, 15th floor, 1140 Avenue of the Americas, New York, NY 10036 (US).
- (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

### Published

With international search report.

(54) Title: PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS

## (57) Abstract

The present invention comprises compounds having general formula (I), wherein:  $Y_1$  is N or CH; Z is selected from the group consisting of alkyl groups such as alkylene groups such as  $CH_2$ ,  $CH_2CH_2$ ,  $CH_2CH_2$ ,  $CH_2CH_2$ ,  $CH_2CH_2$ , alkenyl groups such as  $CH_2CH_2$ , alkynyl groups such

Having thus described the invention, what is claimed is:

1. A method of forming a compound having the general formula I

 $\mathbf{G}$ 

wherein:

Y<sub>1</sub> is N and Y<sub>2</sub> is selected from the group consisting of N or CH

Z is selected from the group consisting of CH<sub>2</sub>;

 $R^1$  and  $R^2$  are independently selected from the group consisting of hydrogen and a  $C_1$ - $C_3$  straight or branched alkyl or a  $C_3$ - $C_8$  cycloalkyl;

R<sup>3</sup> is a C<sub>1</sub> - C<sub>12</sub> straight or branched alkyl;

 $R^4$  is a  $C_3$  -  $C_{10}$  cycloalkyl optionally substituted with OH, or a  $C_3$ - $C_{10}$  cycloalkenyl optionally substituted with OH; and

 $R^8$  is a  $C_1$  -  $C_8$  straight or branched alkyl or a  $C_3$  -  $C_8$  cycloalkyl, optionally substituted with OH;

said method comprising the steps of;

(a) reacting a compound of the formula II

m

wherein  $X^1$  is a carboxamide and  $X^2$  is an amino group; with the benzaldehyde of compound (III)

**(III)** 

wherein R<sup>3</sup> and R<sup>4</sup> are as defined above;
followed by reduction of the resultant compound with a reducing agent to yield compound (IV)

(TV)

wherein Z,  $X^1$ ,  $R^3$ ,  $R^4$  and  $R^8$  are as defined above;

(b) reacting compound (IV) to cause cyclization to compound (V) as set forth below

C

wherein  $Y_1$ , Z,  $R^3$ ,  $R^4$  and  $R^8$  are as defined above and  $Y_2$  is CH when the cyclization reaction occurs using an ester or  $Y_2$  is N when the cyclization reaction occurs using nitrous acid;

WO 99/29694 PCT/US98/26444

(c) transforming said compound (V) to an amine by successive halogenation and displacement to yield compound (I).

- 2. The method of claim 1 wherein said reaction with compound (III) occurs in the presence of an acid.
- 3. The method of claim 2 wherein said acid is selected from the group consisting of tosic acid or p-toluenesulfonic acid.
  - 4. The method of claim 1 wherein said reducing agent is a borane anion.
  - 5. The method of claim 1 wherein said ester is triethylorthoformate.
- 6. The method of claim 1, wherein said halogenating agent is a chlorinating agent.
- 7. The method of claim 1 wherein said compound of formula I is 3-(3-Cyclopentyloxy-4-methoxybenzyl)-6-ethylamino-8-isopropyl-3H-purine.
  - 8. A method of forming a compound having the general formula I

wherein:

Y<sub>1</sub> and Y<sub>2</sub> are CH

Z is selected from the group consisting of CH<sub>2</sub>;

 $R^1$  and  $R^2$  are independently selected from the group consisting of hydrogen and a  $C_1$ - $C_8$  straight or branched alkyl or a  $C_3$ - $C_8$  cycloalkyl;

R³ is a C1 - C12 straight or branched alkyl;

 $R^4$  is a  $C_3$  -  $C_{10}$  cycloalkyl optionally substituted with OH, or a  $C_3$ - $C_{10}$  cycloalkenyl optionally substituted with OH; and

 $R^8$  is a  $C_1$  -  $C_8$  straight or branched alkyl or a  $C_3$  -  $C_8$  cycloalkyl, optionally substituted with OH;

said method comprising the steps of;

(a) reacting a compound of the formula  $\Pi$ 

**(II)** 

wherein  $X^1$  is a ester and  $X^2$  is an amino group; with the benzaldehyde of compound (III)

(m)

wherein R3 and R4 are as defined above;

followed by reduction of the resultant compound with a reducing agent to yield compound (IV)

(TV)

wherein Z, X<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>8</sup> are as defined above;

(b) reacting compound (IV) with a cyclization agent to yield compound (V) as set forth below

**(V)** 

wherein Y<sub>1</sub>, Y<sub>2</sub>, Z, R<sup>3</sup>, R<sup>4</sup> and R<sup>8</sup> are as defined above

- (c) transforming said compound (V) to an amine by successive halogenation and displacement to yield compound (I).
- 9. The method of claim 8 wherein said reaction with compound (III) occurs in the presence of an acid.
- 10. The method of claim 9 wherein said acid is selected from the group consisting of tosic acid or p-toluenesulfonic acid.
  - 11. The method of claim 8 wherein said ester is ethyl ester.
- 12. The method of claim 8 wherein said cyclization agent is ethyl 3-ethoxyacrylate.
- 13. The method of claim 8, wherein said halogenating agent is a chlorinating agent.

WO 99/29694 PCT/US98/26444

14. The method of claim 8 wherein said compound of formula I is 3-(3-Cyclopentyloxy-4-methoxybenzyl)-6-ethylamino-8-isopropyl-3H-purine.

15. A method of forming a compound having the general formula I

**(I)** 

wherein:

Y<sub>1</sub> and Y<sub>2</sub> are CH

Z is selected from the group consisting of  $CH_2$ ,  $CH_2CH_2$ ,  $CH(CH_3)$ , CH=CH, C=C, NH, N(C<sub>1</sub> - C<sub>3</sub> alkyl), O, S, C(O)CH<sub>2</sub> and OCH<sub>2</sub>;

 $R^1$  and  $R^2$  are independently selected from the group consisting of hydrogen and a  $C_1$ - $C_8$  straight or branched alkyl or a  $C_3$ - $C_8$  cycloalkyl;

R<sup>3</sup> is a C<sub>1</sub> - C<sub>12</sub> straight or branched alkyl;

 $R^4$  is a  $C_3$ -  $C_{10}$  cycloalkyl optionally substituted with OH, or a  $C_3$ - $C_{10}$  cycloalkenyl optionally substituted with OH; and

 $R^8$  is a  $C_1$  -  $C_8$  straight or branched alkyl or a  $C_3$  -  $C_8$  cycloalkyl, optionally substituted with OH;

said method comprising the steps of;

(a) reacting a compound of the formula  $\Pi$ 

(II)

wherein  $X^1$  and  $X^2$  are halides; with cyanine to remove one halogen, hydrolyzing the resultant nitrile to an ester, and reacting the resultant ester with compound (X)

(X)

wherein Z,  $R^3$  and  $R^4$  are as defined above, to displace the remaining halogen with the amine, to yield compound (IV)

(IV)

wherein X<sup>1</sup> is an ester and Z, R<sup>3</sup>, R<sup>4</sup> and R<sup>8</sup> are as defined above; (b) reacting compound (IV) with a cyclization agent to yield compound (V) as set forth below

wherein Y<sub>1</sub>, Y<sub>2</sub>, Z, R<sup>3</sup>, R<sup>4</sup> and R<sup>8</sup> are as defined above

**(V)** 

(c) transforming said compound (V) to an amine by successive halogenation and displacement to yield compound (I).

- 16. The method of claim 15 wherein  $X^1$  and  $X^2$  of compound (II) are bromide.
- 17. The method of claim 15 wherein said cyclization agent is ethyl 3-ethoxyacrylate.
- 18. The method of claim 15, wherein said halogenating agent is a chlorinating agent.
  - 19. The method of claim 15 wherein said ester of compound (IV) is ethyl ester.
- 20. The method of claim 15 wherein said compound of formula I is 3-(3-Cyclopentyloxy-4-methoxybenzyl)-6-ethylamino-8-isopropyl-3H-purine.
  - 21. A method of forming a compound having the general formula I

**(II)** 

wherein:

Y<sub>1</sub> and Y<sub>2</sub> are CH

Z is selected from the group consisting of  $CH_2$ ,  $CH_2CH_2$ ,  $CH(CH_3)$ , CH=CH, C=C, NH,  $N(C_1-C_3$  alkyl), O, S,  $C(O)CH_2$  and  $OCH_2$ ;

 $R^1$  and  $R^2$  are independently selected from the group consisting of hydrogen and a  $C_1$ - $C_8$  straight or branched alkyl or a  $C_3$ - $C_8$  cycloalkyl;


R<sup>3</sup> is a C<sub>1</sub> - C<sub>12</sub> straight or branched alkyl;

 $R^4$  is a  $C_3$  -  $C_{10}$  cycloalkyl optionally substituted with OH, or a  $C_3$ - $C_{10}$  cycloalkenyl optionally substituted with OH; and

 $R^8$  is a  $C_1$ -  $C_8$  straight or branched alkyl or a  $C_3$ -  $C_8$  cycloalkyl, optionally substituted with OH;

said method comprising the steps of;

(a) reacting a compound of the formula II



M)

wherein  $X^1$  and  $X^2$  are halides; with cyanine to remove one halogen, reacting the resultant nitrile to a carboxamide, and reacting the resultant carboxamide with compound (X)

(X)

wherein Z, R<sup>3</sup> and R<sup>4</sup> are as defined above, to displace the remaining halogen with the amine, to yield compound (IV)

(TV)

wherein X<sup>1</sup> is a carboxamide and Z, R<sup>3</sup>, R<sup>4</sup> and R<sup>8</sup> are as defined above;

(b) reacting compound (IV) to cause cyclization to compound (V) as set forth below

wherein  $Y_1$ , Z,  $R^3$ ,  $R^4$  and  $R^8$  are as defined above and  $Y_2$  is CH when the cyclization reaction occurs using an ester or  $Y_2$  is N when the cyclization reaction occurs using nitrous acid;

- (c) transforming said compound (V) to an amine by successive halogenation and displacement to yield compound (I).
  - 22. The method of claim 21 wherein X<sup>1</sup> and X<sup>2</sup> of compound (II) are bromide.
- 23. The method of claim 21 wherein said cyclization agent is triethylorthoformate when  $Y_1$  is CH.
- 24. The method of claim 21, wherein said halogenating agent is a chlorinating agent.
- 25. The method of claim 15 wherein said compound of formula I is 3-(3-Cyclopentyloxy-4-methoxybenzyl)-6-ethylamino-8-isopropyl-3H-purine.

# 26. A compound having the general formula (I):

**(I)** 

wherein:

 $Y_1$  and  $Y_2$  are independently selected from the group consisting of CH and N;

Z is selected from the group consisting of  $CH_2$ ,  $CH_2CH_2$ ,  $CH(CH_3)$ , CH=CH, C=C, NH, N( $C_1$ -  $C_3$  alkyl), O, S, C(O) $CH_2$  and OCH<sub>2</sub>;

 $R^1$  and  $R^2$  are independently selected from the group consisting of hydrogen and a  $C_1$ - $C_3$  straight or branched alkyl or a  $C_3$ - $C_3$  cycloalkyl;

 $R^3$  is a  $C_1$  -  $C_{12}$  straight or branched alkyl;

 $R^4$  is a  $C_3$  -  $C_{10}$  cycloalkyl optionally substituted with OH, or a  $C_3$ - $C_{10}$  cycloalkenyl optionally substituted with OH; and

 $R^8$  is a  $C_1$  -  $C_8$  straight or branched alkyl or a  $C_3$  -  $C_8$  cycloalkyl, optionally substituted with OH.

- 27. The compound of claim 26 wherein R<sup>4</sup> is cyclopentyl.
- 28. The compound of claim 27 wherein R<sup>3</sup> is methyl.
- 29 The compound of claim 28 where Z is CH<sub>2</sub>.
- 30. A pharmaceutical composition of a compound of claim 26.
- 31. A method of effecting selective PDE IV inhibition in mammals requiring the same, which comprises administering an effective amount of a compound of claim 26.
- 32. A method of treating a mammal suffering from a disease state selected from the group consisting of asthma, allergies, inflammation, dementia, atopic diseases, rhinitis, and disease states associated with abnormally high physiological levels of cytokine, comprising administering an effective amount of a compound of claim 26.

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US98/26444

			<u> </u>		
	SSIFICATION OF SUBJECT MATTER				
	:C07D 473/34 :544/277				
	to International Patent Classification (IPC) or to both r	ational classification	n and IPC		
B. FIEL	DS SEARCHED			*	
Minimum d	ocumentation searched (classification system followed	by classification sy	mbols)		
U.S. :	544/277				
Documentat	tion searched other than minimum documentation to the	extent that such doc	uments are included	in the fields searched	
<u> </u>	· · · · · · · · · · · · · · · · · · ·	·			
Electronic d	lata base consulted during the international search (na	me of data base and	, where practicable	, scarch terms used).	
CAS Onli	ne .		•		
	,				
Ç. DOC	UMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where app	ropriate, of the rele	vant passages	Relevant to claim No.	
A ·	ER-RHAIMINI et al. The photos	1-32			
	adenines. Photoremovable N-arylmeth				
	containing compounds. Tetrahedron Le				
	31 No. 40, pp 5757-57260, see Compo	ound 2.		·	
	·	•			
		•'		•	
			•	, .	
	•				
·			•	,	
	·	•	٠.		
				,	
	*				
	·			•	
	,	•			
			• •		
Furth	ner documents are listed in the continuation of Box C.	See pate	ent family annex.		
• Sp	secial categories of cited documents:			ternational filing date or priority	
	cument defining the general state of the art which is not considered be of particular relevance		in conflict with the app or theory underlying th	lication but cited to understand e invention	
•	rlier document published on or after the international filing date			ne claimed invention cannot be	
	ocument which may throw doubts on priority claim(s) or which is		cument is taken alone	ered to involve an inventive step	
	ted to establish the publication date of another citation or other ecial reason (as specified)			ne claimed invention cannot be e step when the document is	
	ocument referring to an oral disclosure, use, exhibition or other	combined w		ch documents, such combination	
"P" de	noument published prior to the international filing date but later than so priority date claimed		ember of the same pate		
Date of the	actual completion of the international search	Date of mailing of	the international se	earch report	
22 FEBR	UARY 1997	241	IAR 1999		
Name and	mailing address of the ISA/US	Authorized officer			
Commissi Box PCT	oner of Patents and Trademarks	MARK L. BERCH SCO LAS			
	on, D.C. 20231		,	wic	
Facsimile l	No. (703) 305-3230	Telephone No.	(703) 308-1235		

# INTERNATIONAL SEARCH REPORT

International application No. PCT/US98/26444

		· · · · · · · · · · · · · · · · · · ·				
Box I	Observations where certain	claims were found unse	earchable (Continu	ation of item 1 of	first sheet)	
This inter	mational report has not been es	nablished in respect of certi-	ain claims under Artic	le 17(2)(a) for the fo	llowing reasons:	
ı. 🗂	Claims Nos.:					
·	because they relate to subje	ect matter not required to	be searched by this	Authority, namely:		
					•	•
		•	•			
	*		•			
· —	Olaina Nasa	•				
<sup>2</sup>	Claims Nos.: because they relate to parts of	of the international applica	ation that do not com	ply with the prescrib	ed requirements to suc	h
•	an extent that no meaningfu	al international search can	be carried out, spec	ifically:		
		,			. •	
-		,			0.00	
3.	Claims Nos.:					
	because they are dependent c	saims and are not drafted if	n accordance with the	second and third se	itences of Rule 6.4(a).	
Box II	Observations where unity o	of invention is lacking (	Continuation of iter	n 2 of first sheet)		
This Inte	mational Searching Authority	y found multiple invention	s in this internation	al application, as fo	llows:	
•		•				
Pi	case See Extra Sheet.					
	*		•			
	·		9		•	
	,					
·			-		'.	
	•	-				
					,	•
. —						
1. I I	A s all required additional as	and form were discally wall	h., sh	- :		-L-L1-
	As all required additional seclaims.	arch fees were timely paid	by the applicant, thi	s international searc	h report covers all sean	chable
	claims.	2		*		
2. 🔲		2		*		
2.	claims.  As all searchable claims coulof any additional fee.	uld be searched without ef	fort justifying an add	litional fee, this Aut	hority did not invite pa	yment
2.	claims.  As all searchable claims cou	uld be searched without ef additional search foes w	ffort justifying an add	litional fee, this Aut	hority did not invite pa	yment
2.	As all searchable claims cou of any additional fee.  As only some of the required	uld be searched without ef additional search foes w	ffort justifying an add	litional fee, this Aut	hority did not invite pa	yment
2.	As all searchable claims cou of any additional fee.  As only some of the required	uld be searched without ef additional search foes w	ffort justifying an add	litional fee, this Aut	hority did not invite pa	yment
2.	As all searchable claims cou of any additional fee.  As only some of the required	uld be searched without ef additional search foes w	ffort justifying an add	litional fee, this Aut	hority did not invite pa	yment
2.	As all searchable claims cou of any additional fee.  As only some of the required	uld be searched without ef additional search foes w	ffort justifying an add	litional fee, this Aut	hority did not invite pa	yment
2. 🗍	As all searchable claims cou of any additional fee.  As only some of the required	uld be searched without ef additional search foes w	ffort justifying an add	litional fee, this Aut	hority did not invite pa	yment
2.	As all searchable claims cou of any additional fee.  As only some of the required	uld be searched without ef d additional search foes w h fees were paid, specified	ffort justifying an add ore timely paid by the ally claims Nos.:	ditional fee, this Aut e applicant, this inte	hority did not invite pa	ymeni covers
2.	As all searchable claims could of any additional fee.  As only some of the required only those claims for which the required additional sear restricted to the invention of	uld be searched without ef d additional search foes w h fees were paid, specified	ffort justifying an add ore timely paid by the ally claims Nos.:	ditional fee, this Aut e applicant, this inte	hority did not invite pa	oyment covers
2.	As all searchable claims could of any additional fee.  As only some of the required only those claims for which the required additional sear restricted to the invention of	uld be searched without ef d additional search foes w h fees were paid, specified	ffort justifying an add ore timely paid by the ally claims Nos.:	ditional fee, this Aut e applicant, this inte	hority did not invite pa	ymen coveri
	As all searchable claims could of any additional fee.  As only some of the required only those claims for which the required additional sear restricted to the invention for the restricted to the restricted to the invention for the restricted to t	uld be searched without ef d additional search foes w h fees were paid, specified	fort justifying an adderer timely paid by the ally claims Nos.:  d by the applicant, ms; it is covered by	ditional fee, this Aut e applicant, this inte	hority did not invite pa	ymeni covers

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)★

#### INTERNATIONAL SEARCH REPORT

International application No. PCT/US98/26444

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

Group I - Compounds & Process where Y2=CH, Y1=N.

Claims 1-7 (part), 26-32 (part)

Group II - Compounds & Process where Y2=N, Y1=N

Claims 1-6 (part) and 26-32 (part)

Group III - Compounds where Y2=CH, Y1=CH

Claims 8-13, 15-19, 21-24 and 26-32 (part)

Group IV - Compounds where Y<sub>2</sub>=N, Y<sub>1</sub>=CH

Claims 26-32 (part)

Claims 14, 20 and 25 are improperly dependent as they are outside the scope of the independent claim from which they depend. However, a search of the compound of claim 7 will also afford a search of claims 14, 20 and 25.

The inventions listed as Groups I, II, III and IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The description sets forth that the dialkoxy benzyl is well known in the art. Therefore, it cannot constitute a special technical feature within the meaning of PCT 13.2 as it is not a contribution over the art.

Thus, the special technical feature would appear to reside in the heterocycle attached to the dialkoxy benzyl moiety, however, these heterocycles lack a common core as defined below:

Group I: Imidazotriazine

Group II: Purine

Group III: Imidazopyridines

Group IV: Imidazopyridazines.

In addition, these compounds do not belong to a recognized class of chemical compounds.